Rivaroxaban was one of the most sold pharmaceutical substances in 2020. It is a part of RC REDOL’s portfolio, available to be introduced in your market, since its patent will expire in 2024.
This oral anticoagulant is recommended for the treatment of coronary arteries and peripheral arteries diseases and it is used both as a treatment and as a preventive measure. It acts by avoiding the build-up of clots, which can obstruct the blood vessels and cause AVC’s, strokes or pulmonary embolies. Rivaroxaban requires a medical prescription, and its intake should be watched regularly, to assert efficiency and to prevent unwanted effects.
Join RC REDOL and provide an easier access, in your market, to vital medicines.
RC REDOL, building connections!